SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY

DEODHAR, A., R. BLANCO, Eva DOKOUPILOVÁ, M. VAN DE SANDE, S. HALL, A. WIKSTEN, B. O. PORTER, H. O. RICHARDS, S. HAEMMERLE and J. BRAUNS. SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY. 2020.

Basic information

Original name

SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY

Authors

DEODHAR, A., R. BLANCO, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), M. VAN DE SANDE, S. HALL, A. WIKSTEN, B. O. PORTER, H. O. RICHARDS, S. HAEMMERLE and J. BRAUNS

Edition

2020

---

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

RIV identification code

RIV/00216224:14160/20:00118265

Organization unit

Faculty of Pharmacy

UT WoS

000530661500218

Keywords in English

secukinumab; signs; symptoms; non radiographic axial; spondyloarthritis; prevent study

Tags

rivok, ÚFT

Tags

International impact, Reviewed

---

Abstract

V originále

Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports